Portfolio Manager Factsheet

May 2017

Regeneron Pharmaceuticals higher by 25% (in local currency) in the month after the approval and launch of Dupixent (dupilumab) for the treatment of eczema. Unexpected management changes on the heels of a previous sales scandal pushed Alexion Pharmaceuticals to a new 52-week low.  We believe the company is extremely undervalued at these levels.  

Read more »

Register for email alerts

Worldwide Healthcare Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.